USPTO serial 98921341
LCB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 6, 2026
- Examiner
- OJEYEMI,ASHLEY CHRISTINE
- Law office
- INTENT TO USE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with LCB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Yuseong-gu, Daejeon, KR
Yuseong-gu, Daejeon, KR
Yuseong-gu, Daejeon, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard Y. Kim
Richard Y. Kim Snell & Wilmer L.L.P.One East Washington Street, Suite 2700Phoenix, AZ 85004-2556United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Research and development of vaccines and medicines; biomedical research services; biological research and analysis; research of crude drugs; biochemical research and analysis; bacteriological research and analysis; drug discovery services; Research and development in the field of pharmaceuticals and biotechnology; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; laboratory research in the field of pharmaceuticals; research on the subject of pharmaceuticals; drug development, namely, pharmaceutical drug development services in the fields of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; pharmaceutical research and development; pharmaceutical drug development services; consultancy pertaining to pharmacology; medical and pharmaceutical research services; research in the field of medical preparations; medical research laboratory services; medicine research, namely, medical research services relating to medicines in the fields of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; providing PAAS (platform as a service) featuring computer software used to conduct research and development in the field of pharmaceuticals, biotechnology and drugs; laboratory research services relating to pharmaceuticals; Technology research in the field of medical instruments; testing of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; chemical research and analysis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 6, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 6, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 18, 2025 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Dec 18, 2025 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 16, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 5, 2025 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Dec 5, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| Oct 21, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 21, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 20, 2025 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Oct 15, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 18, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 16, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 9, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 24, 2024 | NWAP | NEW APPLICATION ENTERED | — |